8-K: Milestone Pharmaceuticals Resubmits CARDAMYST NDA to FDA Following Productive Meeting

Milestone Pharmaceuticals Inc. announced the submission of its response to the U.S. Food and Drug Administration's Complete Response Letter for CARDAMYST (etripamil) nasal spray, a key step towards potential approval for paroxysmal supraventricular tachycardia.

Summary

• Milestone Pharmaceuticals Inc. has submitted its response to the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) concerning its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray.
• CARDAMYST is an investigational prescription medication designed for the conversion of acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
• The submission follows a recent "Type A meeting" with the FDA, which management described as productive and providing necessary guidance.
• The FDA is expected to determine the acceptance of the response and a new Prescription Drug User Fee Act (PDUFA) date within the next 30 days.
• The review time for the resubmission is anticipated to be between 2 and 6 months, depending on the FDA's classification of the response.
• If approved, CARDAMYST would be the first and only self-administered therapy for the rapid termination of PSVT episodes, offering patients on-demand care without immediate medical oversight.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company has taken a crucial step towards potential drug approval by submitting its response to the FDA's Complete Response Letter, following a productive meeting. This indicates progress and a clear path forward, despite the inherent risks of drug development.

Positives

• Submission of the response to the FDA's Complete Response Letter (CRL) for CARDAMYST (etripamil) nasal spray, indicating progress towards potential approval.
• A "Type A meeting" with the FDA was productive, providing necessary guidance for the resubmission.
• Management expresses confidence in the value of CARDAMYST, believing it could be the first and only self-administered therapy for PSVT if approved.
• Anticipation of a new Prescription Drug User Fee Act (PDUFA) date this year, signaling a potential timeline for approval.

Risks

• Uncertainty regarding the outcomes of future interactions with the FDA.
• Uncertainty regarding whether and when the NDA for etripamil will be approved by the FDA.
• Uncertainties related to the timing of initiation, enrollment, completion, evaluation, and results of clinical trials.
• Risks and uncertainty related to the complexity inherent in cleaning, verifying, and analyzing trial data.
• Uncertainty whether clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine, and ongoing disputes in Israel and Gaza.
• Overall fluctuations in the financial markets in the United States and abroad.
• Risks related to pandemics and public health emergencies.
• Risks related to the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate.

Future Outlook

Milestone Pharmaceuticals anticipates a new Prescription Drug User Fee Act (PDUFA) date this year, with the FDA review of the resubmission expected to take between 2 and 6 months. The company believes CARDAMYST, if approved, will be the first and only self-administered therapy for PSVT, providing patients with on-demand care and greater control over their condition.

Management Comments

• "Our recent Type A meeting with the FDA was productive and we believe it provided the guidance necessary to submit our response to the CRL directly after the meeting."
• "We appreciate the engagement with the FDA and are excited to prepare for a potential new PDUFA date this year."
• "We continue to believe in the value of CARDAMYST which, if approved, will be the first and only self-administered therapy for the rapid termination of episodes of PSVT."

Industry Context

This announcement is significant within the biopharmaceutical industry, particularly for cardiovascular therapeutics. It highlights the ongoing development of novel, patient-centric treatment approaches, such as self-administered therapies, which aim to improve patient convenience and reduce the burden on healthcare systems. The focus on PSVT and AFib-RVR addresses a specific unmet need for rapid, on-demand management of episodic heart conditions.

Stakeholder Impact

• Shareholders: Potential for increased share value upon drug approval, but also continued risk associated with regulatory uncertainty.
• Patients: If approved, access to a novel, self-administered therapy for PSVT, potentially improving quality of life and control over their condition.
• Healthcare Providers: A new treatment option for PSVT, enabling on-demand care and potentially reducing emergency room visits for acute episodes.

Next Steps

• FDA to determine acceptance of the response and a new Prescription Drug User Fee Act (PDUFA) date within 30 days.
• FDA review of the resubmission, expected to take 2 to 6 months depending on classification.
• Potential approval of CARDAMYST (etripamil) nasal spray for PSVT.

Key Dates

Keywords

Milestone Pharmaceuticals, CARDAMYST, etripamil, PSVT, paroxysmal supraventricular tachycardia, FDA, New Drug Application, NDA, Complete Response Letter, CRL, PDUFA, biopharmaceutical, cardiovascular, nasal spray, self-administered therapy, calcium channel blocker